PROK vs. CALT, AUPH, GYRE, SNDX, ADPT, SYRE, SPRY, NRIX, ELVN, and NTLA
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), Syndax Pharmaceuticals (SNDX), Adaptive Biotechnologies (ADPT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.
ProKidney vs.
ProKidney (NASDAQ:PROK) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
51.6% of ProKidney shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
ProKidney has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
ProKidney has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. ProKidney's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.
ProKidney has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
ProKidney currently has a consensus target price of $5.00, indicating a potential upside of 430.34%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, indicating a potential downside of 1.88%. Given ProKidney's stronger consensus rating and higher probable upside, equities research analysts plainly believe ProKidney is more favorable than Calliditas Therapeutics AB (publ).
Calliditas Therapeutics AB (publ) received 19 more outperform votes than ProKidney when rated by MarketBeat users. However, 57.14% of users gave ProKidney an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
In the previous week, ProKidney had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for ProKidney and 0 mentions for Calliditas Therapeutics AB (publ). ProKidney's average media sentiment score of 1.43 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that ProKidney is being referred to more favorably in the media.
Summary
ProKidney beats Calliditas Therapeutics AB (publ) on 15 of the 18 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
This page (NASDAQ:PROK) was last updated on 3/28/2025 by MarketBeat.com Staff
